Intervention Review

Tamoxifen for early breast cancer

  1. Mike J Clarke*

Editorial Group: Cochrane Breast Cancer Group

Published Online: 8 OCT 2008

Assessed as up-to-date: 10 NOV 2000

DOI: 10.1002/14651858.CD000486.pub2


How to Cite

Clarke MJ. Tamoxifen for early breast cancer. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD000486. DOI: 10.1002/14651858.CD000486.pub2.

Author Information

  1. UK Cochrane Centre, Oxford, UK

*Mike J Clarke, UK Cochrane Centre, National Institute for Health Research, Summertown Pavilion, Middle Way, Oxford, OX2 7LG, UK. mclarke@cochrane.co.uk. clarkem2@TCD.ie.

Publication History

  1. Publication Status: Withdrawn from publication for reasons stated in the review
  2. Published Online: 8 OCT 2008

SEARCH

 
Reason for withdrawal from publication

The most up-to-date results from the EBCTCG overview are available from the Clinical Trial Service Unit and Epidemiological Studies Unit website (http://www.ctsu.ox.ac.uk/projects/ebctcg/) and reprints of the EBCTCG papers can be requested by emailing bc.overview@ctsu.ox.ac.uk

The Early Breast Cancer Trialists Collaborative Group (EBCTCG) conducts periodically updated individual patient data meta-analyses of randomised trials pertaining to the effects of local and systemic therapy on recurrence, second cancers and mortality. These systematic reviews are of the highest quality, are updated every five years and are published in prominent peer-reviewed journals. They represent the best available evidence on the effects of these treatments on relapse, second cancer and death.  

Converting each of the EBCTCG reviews into a Cochrane format as they are updated represents unnecessary duplication of effort and this Cochrane review, which was based on earlier cycles of data collection and analysis by the EBCTCG, has now been withdrawn. To view the published versions of this article, please click the 'Other versions' tab.